Dermatology has evolved from a reliance on off-label medications to the development of a competitive pipeline of disease-modifying biologics and other technologies. Current dermatology dynamics the REACH team is tracking include:
- Expansion of development within less common dermatological conditions beyond Psoriasis and Atopic Dermatitis
- Segmentation of larger dermatological markets into smaller niche markets defined by underlying disease pathophysiology (e.g., Generalized Pustular Psoriasis, Palmoplantar Pustulosis)
- FDA approval of Krystal Biotech’s Vyjuvek, the first topical and redosable gene therapy, for treating Dystrophic Epidermolysis Bullos
Search Dermatology diseases we cover
Disease
Alopecia Areata
Alopecia Areata
Atopic Dermatitis
Atopic Dermatitis
Bullous Pemphigoid
Bullous Pemphigoid
Celiac Disease
Celiac Disease
Chronic Urticaria
Chronic Urticaria
Discoid Lupus
Discoid Lupus
Epidermolysis Bullosa
Epidermolysis Bullosa
Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia
Generalized Pustular Psoriasis
Generalized Pustular Psoriasis
Hidradenitis Suppurativa
Hidradenitis Suppurativa
Lichen Planus
Lichen Planus
Lichen Sclerosus
Lichen Sclerosus
Netherton Syndrome
Netherton Syndrome
Palmoplantar Pustulosis
Palmoplantar Pustulosis
Pemphigus
Pemphigus
Prurigo Nodularis
Prurigo Nodularis
Psoriasis
Psoriasis
Pyoderma Gangrenosum
Pyoderma Gangrenosum
Subacute Cutaneous Lupus
Subacute Cutaneous Lupus
Vitiligo
Vitiligo
Don’t see your disease of interest? Don’t worry! Our experienced team can provide market research support for any rare disease. Reach out to learn how we can help.
Disease
Alopecia Areata
Alopecia Areata
Atopic Dermatitis
Atopic Dermatitis
Bullous Pemphigoid
Bullous Pemphigoid
Don’t see your disease of interest? Don’t worry! Our experienced team can provide market research support for any rare disease. Reach out to learn how we can help.
